France Cuts Reimbursement of Cephalon’s Spasphon, Echos Says
This article is for subscribers only.
The French social security system will cut reimbursement of Cephalon Inc.’s Spasphon drug by half to 15 percent as of Nov. 1, Les Echos reported, citing an official announcement.
The drug, prescribed about 6 million times a year in France, had escaped such a reduction in a previous round of efforts to reduce the country’s healthcare costs, the newspaper said.